Literature DB >> 11934592

Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor.

James E Thompson1, Rose M Cubbon, Richard T Cummings, Linda S Wicker, Robert Frankshun, Barry R Cunningham, Patricia M Cameron, Peter T Meinke, Nigel Liverton, Youmin Weng, Julie A DeMartino.   

Abstract

Jak3 is a protein tyrosine kinase that is associated with the shared gamma chain of receptors for cytokines IL2, IL4, IL7, IL9, and IL13. We have discovered that a pyridone-containing tetracycle (6) may be prepared from trisubstituted imidazole (5) in high yield by irradiation with >350 nm light. Compound 6 inhibits Jak3 with K(I)=5 nM; it also inhibits Jak family members Tyk2 and Jak2 with IC(50)=1 nM and murine Jak1with IC(50)=15 nM. Compound 6 was tested as an inhibitor of 21 other protein kinases; it inhibited these kinases with IC(50)s ranging from 130 nM to >10 microM. Compound 6 also blocks IL2 and IL4 dependent proliferation of CTLL cells and inhibits the phosphorylation of STAT5 (an in vivo substrate of the Jak family) as measured by Western blotting.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11934592     DOI: 10.1016/s0960-894x(02)00106-3

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  81 in total

1.  T cell-, interleukin-12-, and gamma interferon-driven viral clearance in measles virus-infected brain tissue.

Authors:  Samantha R Stubblefield Park; Mi Widness; Alan D Levine; Catherine E Patterson
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

2.  Polycystin-1 regulates STAT activity by a dual mechanism.

Authors:  Jeffrey J Talbot; Jonathan M Shillingford; Shivakumar Vasanth; Nicholas Doerr; Sambuddho Mukherjee; Mike T Kinter; Terry Watnick; Thomas Weimbs
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

3.  Hit clustering can improve virtual fragment screening: CDK2 and PARP1 case studies.

Authors:  Alexey A Zeifman; Victor S Stroylov; Fedor N Novikov; Oleg V Stroganov; Alexandra L Zakharenko; Svetlana N Khodyreva; Olga I Lavrik; Ghermes G Chilov
Journal:  J Mol Model       Date:  2011-11-09       Impact factor: 1.810

4.  Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.

Authors:  Rita Andraos; Zhiyan Qian; Débora Bonenfant; Joëlle Rubert; Eric Vangrevelinghe; Clemens Scheufler; Fanny Marque; Catherine H Régnier; Alain De Pover; Hugues Ryckelynck; Neha Bhagwat; Priya Koppikar; Aviva Goel; Lorenza Wyder; Gisele Tavares; Fabienne Baffert; Carole Pissot-Soldermann; Paul W Manley; Christoph Gaul; Hans Voshol; Ross L Levine; William R Sellers; Francesco Hofmann; Thomas Radimerski
Journal:  Cancer Discov       Date:  2012-05-03       Impact factor: 39.397

5.  Activation of JAK2-V617F by components of heterodimeric cytokine receptors.

Authors:  Anuradha Pradhan; Que T Lambert; Lori N Griner; Gary W Reuther
Journal:  J Biol Chem       Date:  2010-04-02       Impact factor: 5.157

6.  IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes.

Authors:  Michal Marzec; Xiaobin Liu; Monika Kasprzycka; Agnieszka Witkiewicz; Puthiyaveettil N Raghunath; Mouna El-Salem; Erle Robertson; Niels Odum; Mariusz A Wasik
Journal:  Blood       Date:  2007-11-19       Impact factor: 22.113

7.  Noncytolytic clearance of sindbis virus infection from neurons by gamma interferon is dependent on Jak/STAT signaling.

Authors:  Rebeca Burdeinick-Kerr; Dhanasekaran Govindarajan; Diane E Griffin
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

Review 8.  Targeting SH2 domains in breast cancer.

Authors:  Pietro Morlacchi; Fredika M Robertson; Jim Klostergaard; John S McMurray
Journal:  Future Med Chem       Date:  2014       Impact factor: 3.808

9.  Distinct signal codes generate dendritic cell functional plasticity.

Authors:  Kazuhiko Arima; Norihiko Watanabe; Shino Hanabuchi; Mikyoung Chang; Shao-Cong Sun; Yong-Jun Liu
Journal:  Sci Signal       Date:  2010-01-19       Impact factor: 8.192

Review 10.  Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms.

Authors:  Ehab Atallah; Srdan Verstovsek
Journal:  Expert Rev Anticancer Ther       Date:  2009-05       Impact factor: 4.512

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.